Search

Your search keyword '"Rumble, R."' showing total 44 results
Start Over Author "Rumble, R." Database Supplemental Index
44 results on '"Rumble, R."'

10. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.

Author

Moy, Beverly, Rumble, R Bryan, Come, Steven E, Davidson, Nancy E, Di Leo, Angelo, Gralow, Julie R, Hortobagyi, Gabriel N, Yee, Douglas, Smith, Ian E, Chavez-MacGregor, Mariana, Nanda, Rita, McArthur, Heather L, Spring, Laura, Reeder-Hayes, Katherine E, Ruddy, Kathryn J, Unger, Paul S, Vinayak, Shaveta, Irvin, William J Jr, Armaghani, Avan, and Danso, Michael A

Published
2021
Full Text
View/download PDF

14. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline.

Author

Trabulsi, Edouard J., Rumble, R. Bryan, Jadvar, Hossein, Hope, Thomas, Pomper, Martin, Turkbey, Baris, Rosenkrantz, Andrew B., Verma, Sadhna, Margolis, Daniel J., Froemming, Adam, Oto, Aytekin, Purysko, Andrei, Milowsky, Matthew I., Schlemmer, Heinz-Peter, Eiber, Matthias, Morris, Michael J., Choyke, Peter L., Padhani, Anwar, Oldan, Jorge, and Fanti, Stefano

Published
2020
Full Text
View/download PDF

18. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.

Author

Bekelman, Justin E., Rumble, R. Bryan, Chen, Ronald C., Pisansky, Thomas M., Finelli, Antonio, Feifer, Andrew, Nguyen, Paul L., Loblaw, D. Andrew, Tagawa, Scott T., Gillessen, Silke, Morgan, Todd M., Liu, Glenn, Vapiwala, Neha, Haluschak, John J., Stephenson, Andrew, Touijer, Karim, Kungel, Terry, and Freedland, Stephen J.

Published
2018
Full Text
View/download PDF

24. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.

Author

Sepulveda, Antonia R., Hamilton, Stanley R., Allegra, Carmen J., Grody, Wayne, Cushman-Vokoun, Allison M., Funkhouser, William K., Kopetz, Scott E., Lieu, Christopher, Lindor, Noralane M., Minsky, Bruce D., Monzon, Federico A., Sargent, Daniel J., Singh, Veena M., Willis, Joseph, Clark, Jennifer, Colasacco, Carol, Rumble, R. Bryan, Temple-Smolkin, Robyn, Ventura, Christina B., and Nowak, Jan A.

Published
2017
Full Text
View/download PDF

27. Molecular Biomarkers for the Evaluation of Colorectal Cancer

Author

Sepulveda, Antonia R., Hamilton, Stanley R., Allegra, Carmen J., Grody, Wayne, Cushman-Vokoun, Allison M., Funkhouser, William K., Kopetz, Scott E., Lieu, Christopher, Lindor, Noralane M., Minsky, Bruce D., Monzon, Federico A., Sargent, Daniel J., Singh, Veena M., Willis, Joseph, Clark, Jennifer, Colasacco, Carol, Rumble, R. Bryan, Temple-Smolkin, Robyn, Ventura, Christina B., and Nowak, Jan A.

Abstract

Objectives:To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens.

Published
2017
Full Text
View/download PDF

29. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

Author

Basch, Ethan, Loblaw, D Andrew, Oliver, Thomas K, Carducci, Michael, Chen, Ronald C, Frame, James N, Garrels, Kristina, Hotte, Sebastien, Kattan, Michael W, Raghavan, Derek, Saad, Fred, Taplin, Mary-Ellen, Walker-Dilks, Cindy, Williams, James, Winquist, Eric, Bennett, Charles L, Wootton, Ted, Rumble, R Bryan, Dusetzina, Stacie B, and Virgo, Katherine S

Published
2014
Full Text
View/download PDF

30. Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline.

Author

Basch, Ethan, Loblaw, D. Andrew, Oliver, Thomas K., Carducci, Michael, Chen, Ronald C., Frame, James N., Garrels, Kristina, Hotte, Sebastien, Kattan, Michael W., Raghavan, Derek, Saad, Fred, Taplin, Mary-Ellen, Walker-Dilks, Cindy, Williams, James, Winquist, Eric, Bennett, Charles L., Wootton, Ted, Rumble, R. Bryan, Dusetzina, Stacie B., and Virgo, Katherine S.

Published
2014
Full Text
View/download PDF

32. Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2--Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Author

Partridge, Ann H., Rumble, R. Bryan, Carey, Lisa A., Come, Steven E., Davidson, Nancy E., Di Leo, Angelo, Gralow, Julie, Hortobagyi, Gabriel N., Moy, Beverly, Yee, Douglas, Brundage, Shelley B., Danso, Michael A., Wilcox, Maggie, and Smith, Ian E.

Published
2014
Full Text
View/download PDF

33. The effect of posture on the pharmacokinetics of intravenous benzylpenicillin

Author

Rumble, R. H., Roberts, M. S., and Scott, A. R.

Abstract

We have studied the pharmacokinetics of intravenously administered benzylpenicillin in normal subjects during bedrest and during ambulation. The values of total body clearance, mean residence time, and renal clearance found during ambulation were 487.4±100.5 ml/min, 36.23±13.45 min, and 309.4±93.4 ml/min (means ± SD). The corresponding values for bedrest were 543.6±122.6 ml/min, 35.27±10.21 min, and 324.1±145.3 ml/min.

Published
1986
Full Text
View/download PDF

34. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease

Author

Roberts, M., Rumble, R., Wanwimolruk, S., Thomas, D., and Brooks, P.

Abstract

Summary: Plasma aspirin, salicylate and salicyluric acid concentrations were monitored in young, elderly and alcoholic subjects after ingestion of a single 1.2 g dose of soluble aspirin. The plasma aspirin, salicylate and unbound salicylate concentration-time profiles varied considerably between individual subjects. Most of the pharmacokinetic parameters derived from these profiles were not significantly different between young subjects, elderly subjects and subjects with alcoholic liver disease. Individual plasma albumin concentrations provided a better index of the unbound plasma salicylate clearances and salicylate plasma protein binding than the age of the subject or the presence of alcoholic liver disease. Highest unbound plasma salicylate concentrations were found in subjects with the lowest plasma albumin concentrations.

Published
1983
Full Text
View/download PDF

41. Fecal Immunochemical Tests Compared with Guaiac Fecal Occult Blood Tests for Population-Based Colorectal Cancer Screening

Author

Rabeneck, Linda, Bryan Rumble, R, Thompson, Frank, Mills, Michael, Oleschuk, Curtis, Whibley, Alexandra, Messersmith, Hans, Lewis, Nancy, and FIT Guidelines Expert Panel, The

Abstract

Colorectal cancer (CRC) is the second most common cause of cancer deaths in Canadian men and women – accounting for almost 12% of all cancer deaths. In Ontario, it is estimated that 8100 persons were diagnosed with CRC in 2011, and 3250 died from the disease. CRC incidence and mortality rates in Ontario are among the highest in the world. Screening offers the best opportunity to reduce this burden of disease. The present report describes the findings and recommendations of Cancer Care Ontario’s Fecal Immunochemical Tests (FIT) Guidelines Expert Panel, which was convened in September 2010 by the Program in Evidence-Based Care. The purpose of the present guideline is to evaluate the existing evidence concerning FIT to inform the decision on how to replace the current guaiac fecal occult blood test with FIT in the Ontario ColonCancerCheck Program. Eleven articles were included in the present guideline, comprising two systematic reviews, five articles reporting on three randomized controlled trials and reports of four other studies. Additionally, one laboratory study was obtained that reported on several parameters of FIT tests that helped to inform the present recommendation. The performance of FIT is superior to the standard guaiac fecal occult blood test in terms of screening participation rates and the detection of CRC and advanced adenoma. Given greater specimen instability with the use of FIT, a pilot study should be undertaken to determine how to implement the FIT in Ontario.

Published
2012
Full Text
View/download PDF

42. Cancer Care Ontario Colonoscopy Standards: Standards and Evidentiary Base

Author

Rabeneck, Linda, Bryan Rumble, R, Axler, Jeff, Smith, Anne, Armstrong, David, Vinden, Chris, Belliveau, Paul, Rhodes, Kay, Zwaal, Caroline, Mai, Verna, Dixon, Peter, and Cancer Care Ontario’s Colonoscopy Standards Expert Panel, for

Abstract

Colorectal cancer (CRC) is the most common cause of non-tobacco-related cancer deaths in Canadian men and women, accounting for 10% of all cancer deaths. An estimated 7800 men and women will be diagnosed with CRC, and 3250 will die from the disease in Ontario in 2007. Given that CRC incidence and mortality rates in Ontario are among the highest in the world, the best opportunity to reduce this burden of disease would be through screening. The present report describes the findings and recommendations of Cancer Care Ontario’s Colonoscopy Standards Expert Panel, which was convened in March 2006 by the Program in Evidence-Based Care. The recommendations will form the basis of the quality assurance program for colonoscopy delivered in support of Ontario’s CRC screening program.

Published
2007
Full Text
View/download PDF

43. The Role of Gemcitabine in the Treatment of Cholangiocarcinoma and Gallbladder Cancer: A Systematic Review

Author

H Dingle, Brian, Bryan Rumble, R, and C Brouwers, Melissa

Abstract

BACKGROUND: Cholangiocarcinoma and gallbladder cancer are difficult to treat curatively. The treatment of choice is surgery, dependent on detection at a resectable stage. No chemotherapy or radiotherapy options have shown substantial activity. Gemcitabine has demonstrated response in similar cancers. Considering the lack of treatment options for cholangiocarcinoma and gallbladder cancer, a systematic review of the evidence on gemcitabine use for these indications was performed.OBJECTIVE: To perform a systematic review to evaluate the role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer.METHODS: The MEDLINE database was searched (1996 to March 2005) using the medical subject headings 'gemcitabine' and 'gallbladder neoplasms' with results limited to English only. Proceedings from the 1998 to 2004 meetings of the American Society of Clinical Oncology, including the 2004 Gastrointestinal Cancers Symposium, were searched for relevant abstracts. The Canadian Medical Association infobase and the National Guidelines Clearinghouse were also searched for practice guideline reports. Reports were selected and reviewed by two reviewers, and the reference lists from those were searched for additional trials.RESULTS: A total of 13 single-arm phase II trial reports were obtained.CONCLUSIONS: In appropriate patients with gallbladder cancer or cholangiocarcinoma, surgery offers the best chance for survival and should remain the first treatment of choice. For patients not considered candidates for surgery, but willing and able to tolerate chemotherapy alone or in combination with a fluoropyrimidine (such as 5-fluorouracil or capecitabine), gemcitabine appears to be a reasonable alternative to best supportive care, although this conclusion has not been confirmed with a randomized controlled trial.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results